The business model of Bayer AG is focused on the development, manufacturing, and sale of healthcare and agricultural products. As a global pharmaceutical and life sciences company, Bayer AG operates in various sectors such as Pharmaceuticals, Consumer Health, Crop Science, and Animal Health. With its innovative research and development, Bayer AG aims to improve people's lives through its products and solutions. By maintaining a diverse portfolio, strong market presence, and strategic partnerships, the company seeks to address global challenges and contribute to a sustainable future in the fields of healthcare and agriculture.

Bayer AG is primarily active in the pharmaceutical, consumer health, and agricultural industries.

The main competitors of Bayer AG in the market include companies like Johnson & Johnson, Novartis AG, and Sanofi. These companies are also prominent players in the healthcare and pharmaceutical sectors. Bayer AG, a leading life sciences company, competes with these global giants in the areas of pharmaceuticals, consumer health, and crop science. With its diversified portfolio and innovative solutions, Bayer AG strives to stay competitive and maintain market leadership in its various segments.

Bayer AG is a renowned German pharmaceutical and life sciences company with a rich history and strong background. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott, Bayer initially focused on the production of synthetic dyes. Over time, it diversified its portfolio and entered the fields of healthcare, agriculture, and high-tech materials. Today, Bayer is globally recognized for its contributions to medicine, crop protection, and innovative materials. With a commitment to science and sustainability, Bayer continues to improve lives and address global challenges.

Bayer AG has achieved significant milestones throughout its history. Some notable achievements include the development of Aspirin, a widely recognized pain reliever, and the invention of the first oral contraceptive pill. The company also played a crucial role in introducing genetically modified crops, revolutionizing agriculture practices. Additionally, Bayer AG successfully completed the acquisition of Monsanto Company, a leading agricultural biotechnology company. With a rich history of innovation and successful business ventures, Bayer AG continues to make strides in the fields of healthcare, pharmaceuticals, and agriculture, solidifying its position as a global industry leader.

Bayer AG is primarily present in numerous countries and regions worldwide. As a global pharmaceutical and life sciences company, Bayer AG has established a strong presence across Europe, North America, Asia Pacific, and Latin America. Specifically, in Europe, the company has a significant presence in Germany, where its headquarters are located. Furthermore, Bayer AG has a substantial footprint in the United States, contributing to its strong presence in North America. The company's operations extend into key markets in China and other Asian countries as well. With its global reach, Bayer AG aims to serve patients and customers around the world with innovative solutions and products.

Bayer AG represents values of innovation, sustainability, and responsibility. As a global company, Bayer focuses on providing solutions that improve people's lives and contribute to societal progress. Their corporate philosophy emphasizes ethical behavior, fairness, and integrity in all business activities. Bayer is committed to scientific excellence and advances in areas such as healthcare, agriculture, and nutrition. They strive to create a more sustainable future by developing environmentally friendly products and reducing their ecological footprint. With a strong emphasis on research and development, Bayer AG aims to continuously drive growth and make a positive impact worldwide.

Analysts currently set an average price target of 42.36 EUR for the Bayer stock (median: 41.92 EUR), implying -13.8 % versus the latest price. The consensus is based on 29 analyst ratings.

Bayer Analyst Price Targets 2026

29 analysts currently rate the Bayer stock: 17 recommend buying, 10 holding and 2 selling. For 2026, analysts expect Bayer to generate revenue of 45.55 B EUR and earnings per share of 4.42 EUR.

Bayer Analyst Price Targets 2026

The Bayer share (BAYN.DE) is listed on 14 stock exchanges, including: NASDAQ (BAYZF), XETRA (BAYN.DE), Frankfurt (BAYN.F), München (BAYN.MU), Stuttgart (BAYN.SG), Düsseldorf (BAYN.DU), Berlin (BAYN.BE), Hamburg (BAYN.HM).

The Bayer AG is a German company that operates in various business sectors. The company is active in the chemical and pharmaceutical industry and offers a wide range of products and services. Pharma and Health One of Bayer's most well-known business sectors is pharma and health. The company produces a variety of medications used for treating diseases such as diabetes, cancer, cardiovascular diseases, and many more. The most well-known medications include the pain reliever Aspirin, the contraceptive Yaz, and the cancer medication Nexavar. Crop Science Another important business sector of Bayer is Crop Science. Bayer produces seeds and plant protection products for the agribusiness sector. The company offers a wide range of products for the cultivation of crops such as grains, vegetables, and fruits. The company also supports farmers in the efficient use of water and energy for sustainable agriculture. Bayer Crop Science is a key player in the global agricultural landscape. Consumer Health Bayer also has a Consumer Health business sector that offers a variety of products for health and personal care. The company produces medications for minor illnesses and diseases such as cold and flu, as well as self-care products such as pain ointments, antiseptics, skin creams, and vitamins. The most well-known products include Coppertone sunscreen and the pain reliever Aleve. Animal Health Bayer also utilizes its expertise in animal health by producing medications and services. This business sector focuses on the health and well-being of livestock and pets. The company has an extensive range of products for the treatment and prevention of disease-related risks in pets as well as livestock. Bayer also has various business sectors focusing on the production of chemicals, materials, and technologies for the production of plastics, paints, adhesives, high-tech products, and more. Overall, Bayer AG's business model is oriented towards strong diversification to minimize risks and seize opportunities in various markets. With a wide range of products and a strong presence in different regions, Bayer continuously generates a high volume of revenue through its strong research and development and is an important company for the German economy.

The expected revenue of Bayer is 45.55 B EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Bayer is 4.34 B EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Bayer is currently 10.77. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Bayer stock.

The price-to-sales ratio (P/S) of Bayer is currently 1.03. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Bayer stock.

The Eulerpool Quality Score for Bayer is 1/10.

The ISIN of Bayer is DE000BAY0017. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Bayer is BAY001. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Bayer is BAYN.DE. The ticker symbol is used to trade Bayer shares on the stock exchange.

Over the past 12 months, Bayer paid a dividend of 0.11 EUR . This corresponds to a dividend yield of about 0.23 %. For the coming 12 months, Bayer is expected to pay a dividend of 0.11 EUR.

The current dividend yield of Bayer is 0.23 %.

Bayer pays a dividend, distributed in the months of , , , .

Bayer paid dividends every year for the past 36 years.

For the upcoming 12 months, dividends amounting to 0.11 EUR are expected. This corresponds to a dividend yield of 0.22 %.

Bayer is assigned to the 'Health' sector.

To receive the latest dividend of Bayer from amounting to 0.11 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Bayer distributed 0.11 EUR as dividends.

The dividends of Bayer are distributed in EUR.